Nanobiotix Announces Pricing of Oversubscribed €85m Global Offering

PARIS, France and CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “ Nanobiotix ” or the “ Company ”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announces the pricing of its previously announced global follow-on offering, consisting of (i) a public offering of 225,373 American Depositary Shares (“ ADSs ”), each ADS representing one ordinary share, €0.03 nominal value per share (each an “ Ordinary Share ”), of the Company, in the United States (the “ U.S. Offering ”) at an offering price of $38.98 per ADS, and (ii) an offering of (a) 1,959,289 Ordinary Shares and (b) 345,099 pre-funded warrants to subscribe for one Ordinary Share each (the “ PFW ”), exclusively to “qualified investors” in Europe (including France) within the meaning of Article 2(e) of Regulation (EU) 2017/1129, as amended (the “ Prospectus Regulation ”), and certain other countries (excluding the United States and Canada) (the “ International Offering ”, together with the U.S. Offering, the “ Global Offering ”), at an offering price of €33.60 per Ordinary Share and €33.57 per PFW.